Evinacumab

Angiopoietin-like 3 Inhibitor — CARDIOVASCULAR SYSTEM

Key facts

Evinacumab is a drug in the Angiopoietin-like 3 Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 2021. Its mechanism of action is classified as Angiopoietin-like 3 Inhibitors. DrugCentral lists 1 molecular target, including ANGPTL3. Recorded indications include Homozygous familial hypercholesterolemia.

• Drug class: Angiopoietin-like 3 Inhibitor.
• Mechanism of action: Angiopoietin-like 3 Inhibitors.
• Molecular targets: ANGPTL3 (1 listed in DrugCentral).
• Indications: Homozygous familial hypercholesterolemia.
• ATC code: C10AX17 (Other lipid modifying agents).

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Homozygous familial hypercholesterolemia

Mechanism & targets

• Mechanism of action (MoA): Angiopoietin-like 3 Inhibitors
• Established pharmacologic class: Angiopoietin-like 3 Inhibitor

Molecular targets (1)

Target	Gene	Action	Activity
Angiopoietin-related protein 3	ANGPTL3	inhibitor	Kd 9.04

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
2021-06-17	EMA	—	Regeneron Ireland Designated Activity Company (DAC)
2021-02-11	FDA	—	REGENERON PHARMACEUTICALS	Yes

ATC classification

ATC code	Therapeutic hierarchy
C10AX17	CARDIOVASCULAR SYSTEM › LIPID MODIFYING AGENTS › LIPID MODIFYING AGENTS, PLAIN › Other lipid modifying agents

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

• EMA label: LDLR
• FDA label: LDLR

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Hepatic steatosis	87.9
International normalised ratio increased	59.2

Chemical structure

• Molecular formula: —
• Molecular weight: —
• CAS number: —
• InChIKey: —
• PubChem CID: —

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Evinacumab used for?

DrugCentral lists the following indications for Evinacumab: Homozygous familial hypercholesterolemia.

How does Evinacumab work?

Evinacumab is classified as Angiopoietin-like 3 Inhibitors; its molecular targets in DrugCentral include ANGPTL3 (inhibitor).

When was Evinacumab first approved?

Evinacumab was first approved by the FDA in 2021.

What drug class does Evinacumab belong to?

Evinacumab is in the Angiopoietin-like 3 Inhibitor class.

Sources

• DrugCentral drug card 5449 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL3545191 — compound record and bioactivity
• DrugBank DB15354 — drug record
• FDA UNII T8B2ORP1DW — substance identity
• DailyMed: FDA labels for Evinacumab — current prescribing information (label search)
• UniProt Q9Y5C1 (ANGPTL3) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
• PharmGKB / CPIC — pharmacogenomic label annotations

How this page is built: methodology · editorial policy & corrections.